Developing novel treatments for mental health via pychedelic Therapies...
Woke Pharmaceuticals is on a mission to change the status quo in the treatment of mental health.
Woke is focused on working with leading universities and research institutes to develop psychedelic therapies to help those who struggle with mental health.
Sign up to receive the latest announcements on Woke Pharmaceuticals....
Latest Announcements
19.05.22
Media
Could psychedelic drugs be the key to treating mental health issues?
Initial focus on psilocybin for depression based on evidence of efficacy. Proprietary formulations to enhance release profile of active drug and secure Intellectual Property
WP001Psilocybin (low dose)Rapid release CapsuleModerate DepressionCommencing Phase IIB trial in H2 CY2022Monash University MMIC
Maquaire University
WP002Psilocybin (high dose)Rapid release TabletTreatment-Resistent DepressionCommencing Phase IIB trial in Late CY2022Monash University MMIC
Imperial College London
Drug Science (UK)
WP003LSD AnalogueAnxiety, Substance Abuse, PTSDResearchUniversity of Western Australia
Partnerships with leading clinicians and formulation experts
The Market | Unmet Medical Need Growing due to Pandemic
Over 700 million people are affected globally with some sort of mental illness, eg: depression, anxiety, PTSD, addiction or eating disorder
Source: The World Health Organisation
Global economic costs due to mental heath disorders estimated to be USD$800 Billion direct and US$1.7 Billion indirect
Source: National Centre for Biotechnology Information
1 IN 4 PEOPLE WILL SUFFER MENTAL HEALTH DISORDERS
25% of adults in the world will be affected by mental or neurological disorders at some point in their lives
Source: World Health Organisation
ACN: 651 290 729
Address: Suite 301, 10 Bridge St, Sydney NSW 2000 Australia
